Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials

Table 3

Clinical trials examined assessing the influence of treatment with memantine in moderate-severe AD.

First author and no. in the list of references	Severity	Mean age years	Mean MMSE at baseline	Duration of the study	𝑁	Test
Fox et al. 2012 [17]	MMSE ≤ 19	Placebo: 84.4 (6.6); Memantine: 84.9 (6.7)	Placebo: 7.3 (6.4); Memantine: 7.3 (6.2)	12 weeks	149	MMSE; SIB; NPI; CMAI; CGI-C
Förstl et al. 2011 [18]	MMSE ≤ 27	75.5±7.5	17.1±5.5	6 months	4305	MMSE; IADL
Herrmann et al. 2011 [19]	MMSE 0–15	85.81±3.7	8.74±6.71	3 months	24	NPI; CGI-C
Schulz et al. 2011 [20]	MMSE ≤ 20	Memantine: 77.8±8; Placebo: 76±6	16.0 (3.7)	12 weeks	93	CERAD-NP; ACDS-ADL-sev; CGI-C
Rainer et al. 2011 [21]	MMSE < 20	77.6±7.569	11.75±6.38	4 months	350	MMSE; CGI
Wilcock et al. 2008 [22]	MMSE 14–3	Memantine: 76.9 (8.4); Placebo: 76.7 (7.9)	Memantine: 9.2 (3.3); Placebo: 9.6 (3.1)	6 months	593	MMSE; SIB; NPI; ACDS-ADL-sev; CIBIC-plus